Victor Ilog
Psychiatric/Mental Health · El Paso, TXNPI 1134628563
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,996 of the $166,795 with a category attached, or 77.9%. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 35.6% of the total. 2025 is the largest year on record at $76,290, more than ten times the $2,020 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $228.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$59K
- Alkermes, Inc.$42K
- Johnson & Johnson$19K
- Neurocrine Biosciences, Inc.$15K
- Teva Pharmaceuticals USA, Inc.$15K
- AbbVie$13K
- plus $4K from 15 others
What the payments were for
- Consulting fees$11,2467%
- Speaking & faculty fees$129,99678%
- Travel & lodging$11,9577%
- Food & beverage$13,2398%
- Education$3570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 166 | $59,413 |
| Alkermes, Inc. | 120 | $41,575 |
| Johnson & Johnson | 43 | $19,257 |
| Neurocrine Biosciences, Inc. | 75 | $14,858 |
| Teva Pharmaceuticals USA, Inc. | 53 | $14,638 |
| AbbVie | 80 | $12,867 |
| Corium, LLC | 56 | $1,087 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $925 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $463 |
| AstraZeneca | 4 | $407 |
| Lundbeck LLC | 30 | $364 |
| Axsome Therapeutics, Inc. | 13 | $249 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $191 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $120 |
| Sunovion Pharmaceuticals Inc. | 6 | $78 |
| Supernus Pharmaceuticals, Inc. | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Indivior Inc. | 2 | $45 |
| Eisai Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$136,267
- REXULTI$37,991
- ARISTADA$27,737
- ABILIFY MAINTENA$19,757
- INVEGA SUSTENNA$18,507
- INVEGA TRINZA$18,065
- ABILIFY ASIMTUFII$14,978
- INGREZZA$13,645
- UZEDY$13,431
- VRAYLAR$11,250
- ARISTADA INITIO$2,395
- BREZTRI$211
- SPRAVATO$125
- FARXIGA$125
- Fanapt$125
- CAPLYTA$100
How this compares
$166,795 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 184 | $295,594 |
| Abilify MaintenaAripiprazole | 82 | $221,355 |
| LybalviOlanzapine/Samidorphan Malate | 133 | $215,151 |
| AristadaAripiprazole Lauroxil | 60 | $177,940 |
| Invega TrinzaPaliperidone Palmitate | 20 | $173,160 |
| IngrezzaValbenazine Tosylate | 22 | $170,182 |
| Invega SustennaPaliperidone Palmitate | 69 | $168,675 |
| Austedo XrDeutetrabenazine | 24 | $165,662 |
| Abilify AsimtufiiAripiprazole | 20 | $107,751 |
| CaplytaLumateperone Tosylate | 57 | $94,530 |
| BelsomraSuvorexant | 83 | $36,223 |
| UzedyRisperidone | 12 | $34,195 |
| VraylarCariprazine Hcl | 19 | $29,282 |
| Aripiprazole | 203 | $27,559 |
| Divalproex Sodium ErDivalproex Sodium | 274 | $21,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena, Abilify Asimtufii | $59,413 | $624,699286 claims |
| Alkermes, Inc.Lybalvi, Aristada | $41,575 | $393,091193 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $19,257 | $341,83589 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $14,638 | $199,85736 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14,858 | $170,18222 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $925 | $94,53057 claims |
| AbbVieVraylar | $12,867 | $29,28219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $463 | $20,45919 claims |
| Indivior Inc.Suboxone | $45 | $8,67312 claims |
| Lilly USA, LLCOlanzapine | $14 | $8,207211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in El Paso
- Alfredo ArellanoEl Paso$55K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.